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Increased cellular Na/H antiport activity has been documented in
various cell types from hypertensive humans and rats. This membrane
abnormality may be associated with the thickening of the vascular
media of resistance vessels. Such an abnormality has also been dem-
onstrated in cells from type I diabetic patients with nephropathy, and
may indicate the predisposition to essential hypertension in such
patients. We now demonstrate the importance of the rate-limiting
enzyme for cholesterol and isoprenoid synthesis, 3-hydroxy-3-methyi-
glutaryl coenzyme A reductase, in determining cellular Na4/H an-
tiport activity. This finding may have application in the future treatment
of diabetic patients with proteinuria.
Clinical proteinuria in type 1 diabetes is associated with a
very poor prognosis [1]. Only a third of all insulin-dependent
diabetic patients develop this complication [2, 3] and the
pathogenesis may not be related purely to poor glycemic
control [4], although this is one important factor. Blood pres-
sure is elevated in patients with established diabetic nephrop-
athy, but is also observed in those at risk of nephropathy before
any evidence of renal impairment [5, 6]. There is evidence of
familial clustering of diabetic nephropathy [7]. This suggests
that a genetic predisposition to essential hypertension may
render insulin-dependent diabetic patients with poor metabolic
control susceptible to nephropathy.
The study of such a genetic predisposition to essential
hypertension in diabetic nephropathy has been facilitated by
widespread documentation of a membrane transport abnormal-
ity, an elevated red cell Li/Na countertransport 18]. This
increased countertransport is clearly determined by genetic
factors [9]. In insulin-dependent diabetic patients with nephrop-
athy, especially those with poor glycemic control, the red cell
Lit'Na countertransport is elevated [10, 11].
Although red cell LP/Na countertransport is widely used as
a marker of essential hypertension, the membrane carrier that
mediates this transport is unclear. Mahnensmith and Aronson
proposed that it may be a mode of operation of the ubiquitous
Na/H antiport, a transporter that normally exchanges exter-
nal Na for internal H, and thus regulates cellular pH and
volume [12].
In human hypertension, leucocyte Na/H antiport activity
is elevated [13, 141. This in vitro evidence is further supported
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by the non-invasive measurement of intracellular pH in human
forearm skeletal muscle by phosphorus nuclear magnetic reso-
nance, showing accelerated recovery from intracellular meta-
bolic acidosis in patients with essential hypertension [15].
Increased leucocyte Na/H antiport activity has also been
shown in type 1 diabetic patients with nephropathy, but those
with normoalbuminuria have similar rates of Na/H exchange
to normal non-diabetic controls [16]. These findings resemble
those in human essential hypertension, reinforcing the concept
that susceptibility to this complication of diabetes may be
associated with predisposition to hypertension.
Cellular Na/H antiport activity clearly depends on two
post-translational processing events, namely phosphorylation
and N-linked enzymatic glycosylation [17]. The effect of stau-
rosporine, an inhibitor of phosphorylation of the Na/H
antiport by protein kinase C, has been studied in leucocytes
from patients with diabetic nephropathy [18]. This restored
elevated cellular Na/H antiport activity to values not differ-
ent from normal controls, with a small but significant effect on
cells from normoalbuminuric diabetic patients. Leucocytes
from non-diabetic controls were not affected [18]. It has been
shown that hyperglycaemia per se could lead to increased
protein kinase C activity from generation of diacyl glycerol [191.
Currently, non-toxic modulators of cellular kinases are not
available.
N-linked enzymatic glycosylation and the activity of the
Na'7H antiport may be affected by swainsonine, an inhibitor
of cx-D-mannosidase II [20], but this has many adverse effects in
vivo. The production of oligosaccharide side chains for enzy-
matic glycosylation is very dependent on dolichol, an iso-
prenoid that serves as a carrier for the growing chains [211.
Dolichol itself is a product of 3-hydroxy-3-methylglutaryl coen-
zyme A reductase (HMG CoA reductase), the rate limiting
enzyme for endogenous cholesterol synthesis [21].
The prevalence of hypercholesterolemia in essential hyper-
tension [22] and diabetic renal disease is higher than expected
[23, 24], possibly indicating an abnormality in the control of the
mevalonate synthetic pathway. Such an anomaly may also
account for changes in the membrane transport markers of
hypertension. We have therefore investigated: (1) the relation-
ships between plasma lipoprotein cholesterol levels and leuco-
cyte Na/H antiport activity in normal controls, diabetic
patients with and without nephropathy; (2) the effects of a
potent HMG CoA reductase inhibitor pravastatin, on the mem-
brane transport activity of the Na'IH antiport glycoprotein in
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vitro. Modulation of the activity of this transporter could be of
potential benefit to the progression of diabetic nephropathy.
Methods
Materials
Fetal bovine serum, penicillin and streptomycin were from
Flow Laboratories Ltd. (Rickmansworth, Herts., UK). Glu-
tamine, nigericin, non-esterified fatty acid free bovine serum
albumin (BSA), mevalonate, N-2-hydroxyethyl-piperazine
ethanesulphonic acid (HEPES) and RPMI 1640 and TC199
tissue culture media were from the Sigma Chemical Co. (Poole,
Dorset, UK). Fetal bovine serum was dialyzed with 140 mmol/
liter saline for 72 hours before use. Bis-carboxyethyl carboxy
fluorescein acetoxymethyl ester (BCECF-AM) was purchased
from Cambridge Bioscience (Cambridge, UK). Ethyl isopropyl
amiloride (EIPA) was a gift from Merck, Sharpe and Dohme
(Rahway, New Jersey, USA), and pravastatin was obtained
from Bristol-Myers Squibb Pharmaceuticals Ltd. (Hounslow,
Middlesex, UK).
Normal controls were recruited from our hospital staff. They
were matched for age, body mass index and blood pressure
(BP) with insulin-dependent diabetic patients who were diag-
nosed with and without albuminuria. Albuminuria was defined
as an albumin/creatinine ratio greater than 2 mg/mmol on three
separate early morning urine specimens taken a month apart, in
the absence of ketoacidosis and urinary tract infection. All
subjects attended the study after an overnight fast, and /2 hour
after insertion of an intravenous cannula, blood was taken for
fasting lipoprotein determinations and leucocyte Na/H an-
tiport activity.
Human Epstein Barr virus transformed lymphoblasts were
obtained from Dr. M. Ameen (MRC Clinical Pharmacology
Unit, Radcliffe Infirmary, Oxford, UK). These cells were
cultured in HCO buffered RPMI 1640 medium with 10%
dialyzed fetal bovine serum, 1 mmol/liter glutamine, iø lU/liter
penicillin and 100 mg/liter streptomycin (pH 7.4 in 95% air, 5%
C02). Cell density was kept between 0.5 and 1 x 106 cells/ml.
Measurement of intracellular pH and Na/H antiport
activity
Human peripheral blood leucocytes were isolated by dextran
sedimentation as previously described [14, 16, 18]. Human
lymphoblasts were cultured in RPM! 1640 medium (containing
10% dialyzed fetal bovine serum) with or without the HMG
CoA reductase inhibitor, pravastatin (final concentration 50
mg/liter). Cells were studied two days after addition of the
inhibitor. In other experiments, we examined the effect of
adding 1 mmol/liter mevalonate concurrently with the pravas-
tatin. The RPM! 1640 medium contained 30 mg/liter cholesterol,
to ensure that observed effects were not due to cellular choles-
terol deficiency.
The leucocytes or lymphoblasts were loaded with the pH
sensitive fluorophore BCECF in the ester form by incubating
them with 10 mol/liter BCECF-AM in TC199 tissue culture
medium for 1/2 hour at 37°C. The cells were then washed three
times in TC199 (containing 10% serum) and left in this medium
for 1/2 hour at room temperature before making any measure-
ments.
Readings of resting intracellular pH were performed in buff-
ered saline composed of(in mmol/liter) NaCI 140, KC1 5, CaCl2
1.8, MgSO4 0.8, glucose 5, HEPES 15, BSA 1 g/liter, pH 7.4.
Cells were stirred in thermostatted cuvettes (37°C). The two
excitation wavelengths were set at 500 and 439 nm (slit width 5
nm) with emission at 530 nm (slit width 2 nm) in a single photon
counting Deltascan fluorometer (Photon Technology Interna-
tional Inc., South Brunswick, New Jersey, USA). The 500/439
fluorescence ratio was used for subsequent calculation of intra-
cellular pH, after constructing a calibration curve with cells
immersed in isotonic KCI buffer [composed of (in mmol/liter)
KC1 140, CaCI2 1.8, MgSO4 0.8, glucose 5, HEPES 15, with 2
tmol/liter nigericin and 5 jimol/liter monensin] [14, 16, 18].
Human leucocyte Na/H antiport activity was then mea-
sured with intracellular pH clamped to 6.0 using the isotonic
KCI buffer containing nigericin. In studies on lymphoblasts,
intracellular pH was clamped to 6.2 as detailed above. Clamped
intracellular pH ranging from 6.0 to 6.2 was chosen, as the
maximal transport capacity of the Na/H antiport in these
cells occurred in this pH range. After five minutes, the iono-
phore was removed by washing with an identical KC1 buffer
containing BSA (1 g/liter) without the nigericin and monensin.
Total H exchange was measured by exposing the cells to
isotonic NaCl buffer (pH 7.4) and amiloride-insensitive H
exchange measured after addition of 10 tmol/liter EIPA [14,
161. Buffering power at an internal pH of 6.0 or 6.2 was
measured by addition of 10 mmol/liter (NH4)2 SO4 and measur-
ing the change in intracellular pH. Amiloride-sensitive H
effiux (in mmol/liter/min) was calculated as the product of
buffering power and the external Na dependent rate of change
of intracellular pH, and represents efflux via the Na/H
antiport.
Lipoprotein determinations
Plasma was analyzed for total, high (HDL) and low density
lipoprotein (LDL) cholesterol levels using methods previously
described [25].
Statistics
The data were analyzed using an Oxstat statistics package
(Microsoft Corporation, Reading, UK) using an unpaired Stu-
dent's t-test. Results are presented as means (SD) unless other-
wise stated, and all P values are two-tailed. Spearman correla-
tion coefficients were also calculated.
Results
Relationships between plasma lipoprotein levels and
leucocyte Na/H antiport activity in normal and diabetic
subjects
The characteristics of the normal controls, diabetic patients
with and without nephropathy are shown in Table 1. Although
matched for age, body mass index and blood pressure, there
was a male predominance in the diabetic nephropathy group.
The triglyceride and cholesterol levels were similar in all groups
of subjects. Leucocyte Na/H antiport activity was signifi-
cantly raised in patients with nephropathy compared to normal
controls (P < 0.001) or normoalbuminuria diabetic patients (P
<0.01).
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Number female/male
Body mass index kg m2
Age years
Systolic blood pressure
mm Hg
Diastolic blood pressure
mm Hg
Duration of diabetes years
Plasma creatinine mol/
liter
Urinary albumin/creatinine
ratio mg/mmol
Fasting plasma glucose
mmol/liter
Fasting plasma
triglycerides mmol/liter
Fasting plasma cholesterol
mmol/liter
Plasma HDL cholesterol
mmol/liter
Plasma LDL cholesterol
mmol/liter
Plasma VLDL cholesterol
mmol/liter
Leucocyte Na/H
antiport activity mmolliter' min'
11/12
23.8 (4.2)
40(15)
121 (10)
8/7
23.5 (2.4)
38(13)
127 (12)
3/15
23.5 (2.6)
34(11)
129 (18)
78 (9) 73 (6) 79 (12)
—
83 (12)
23,1 (10.8)
79 (10)
20.6 (8.7)
91(15)
0.30 (0.72) 0.47 (1.22) 10.7 (34,7)a
5.0 (0.6) 12.6 (4.2r 15.3 (5.2)a
0.98 (0.66) 0.78 (0.20) 1.01 (0.46)
4.81 (0.99) 4.93 (1.08) 4.93 (0.85)
1.39 (0.45) 1.62 (0.43) 1.42 (0.28)
2.84 (1.17) 2.95 (0.95) 2.98 (1.05)
0.43 (0.41) 0.26 (0.16) 0.53 (0.46)
53.7 (6.1) 55.3 (12.1) 72.2 (16.4)a
Leucocyte Na/H antiport activity was measured after intracellular
pH was clamped to 6.0 by the double ionophore technique described in
the text. Means (SD) are reported except for the urinary albumin!
creatinine ratio, where geometric means (geometric mean I SD) are
reported.
a P < 0.001 compared to normal controls
In the normal controls, there was a significant negative
correlation between total plasma cholesterol and leucocyte
Na/H antiport activity (r = —0.81, P < 0.001). Figure 1
shows the highly significant negative correlation between LDL
cholesterol and leucocyte Na/H antiport activity in the
normal controls (r = —0.81, P < 0.001). This negative corre-
lation was not seen in the diabetic patients with nephropathy,
where leucocyte Na/H antiport activity remained elevated as
LDL cholesterol rose in the normal range (Fig. 1). In normoal-
buminuric diabetic patients, a positive correlation was found
between total cholesterol and leucocyte Na/H antiport ac-
tivity (r = 0.68, P < 0.05). This was mainly due to the
correlation between LDL cholesterol and Na/H antiport
activity (r = 0.80, P < 0.001, Fig. 1).
Effect ofpravastatin on lymphoblast intracellular pH and
Na/H antiport activity
Pravastatin had a highly significant inhibitory effect on the
Na/H antiport activity of human lymphoblasts (Fig. 2). After
two days of incubation with 50 mg/liter pravastatin, lympho-
blasts showed a reduced intracellular pH and reduced Na/H
antiport activity measured when internal pH was clamped to 6.2
(P < 0.001 for both). This effect on cultured cells was not
nonspecifically toxic since the inhibitory effect on the lympho-
blast Na/H antiport activity was totally prevented (Fig. 2)
and intracellular pH remained similar to the normal control cells
when I mmol/liter mevalonate was introduced together with the
pravastatin (50 mg/liter). Mevalonate bypasses the blockade of
HMG CoA reductase by pravastatin.
Discussion
In the normal group, there was a highly significant negative
correlation between leucocyte Na/H antiport activity and
total or LDL cholesterol levels. This may indicate a direct effect
of cholesterol on membrane fluidity, as increasing cellular
cholesterol content in vitro may reduce Na/H antiport activ-
ity 1261. However, large increases in cellular cholesterol are
necessary [26]. In vivo, leucocytes exposed to higher plasma
LDL cholesterol levels would take up more cholesterol via
LDL receptors [27], and this may then reduce endogenous
cellular cholesterol synthesis via suppression of HMG CoA
reductase activity [27] with suppression of dolichol and hence
N-linked oligosaccharide glycoprotein synthesis. Since the
Na/H antiport is a glycoprotein [17], a lower cellular
Na/H1 antiport activity would result in subjects with a raised
plasma LDL level.
In this study, the normal subjects and the diabetic patients
with and without albuminuria had comparable levels of total,
HDL and LDL cholesterol. Others have found increased (11 to
14%) total, LDL and VLDL cholesterol in diabetic nephropathy
[24]. Our negative finding may have resulted from patient
selection from a smaller group of patients. Nevertheless, the fall
in activity of the leucocyte Na/H antiport activity with rising
plasma LDL levels seen in normal subjects did not occur in
diabetic patients with nephropathy over the same range of LDL
cholesterol levels. Moreover, normoalbuminuric diabetic sub-
jects showed a paradoxical positive correlation between leuco-
cyte Na/H antiport activity and plasma total and LDL
cholesterol. At present, the pathogenesis of this failure of LDL
cholesterol to down regulate the activity of the Na/H antiport
is unknown, but changes in the regulation of isoprenoid synthe-
sis in the mevalonate pathway may be involved.
The relationship of the key enzyme of endogenous choles-
terol synthesis, HMG CoA reductase, to cellular Na/H
antiport activity was studied in human lymphoblasts. The
maximal transport capacity of the antiport at an internal pH of
6.2 of these lymphoblasts were in the same range that we found
for lymphocytes [28], and below that of neutrophils [28]. As the
data on normal and diabetic patients were from mixed leuco-
cytes (predominantly neutrophils), this explains the higher H
effiux rate in mixed leucocytes compared to the human lympho-
blasts, In vitro, we have shown that a specific inhibitor of HMG
CoA reductase, pravastatin, inhibited Na/H antiport activity
leading to intracellular acidification. Mevalonate bypassed this
enzyme in the pathway and prevented the inhibitory effects of
the drug on the Na/H antiport activity. The inhibitory effect
on the Na/H antiport was not due to cellular cholesterol
depletion, since cholesterol was present in the culture medium.
We have also previously shown that cellular cholesterol deple-
tion leads to activation of the Na/H antiport and not inhibi-
tion [261. One interpretation could be that the effect of pravas-
tatin on NaF/H± antiport activity was not due to alterations in
Table 1. Clinical characteristics and leucocyte Na/H antiport
activity of diabetic patients with and without nephropathy and the
normal controls
Diabetic subjects
With
Normal normoalbu- With
subjects minuria nephropathy
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cellular cholesterol but to another isoprenoid product of meval-
onate such as dolichol [27, 29] which is essential for the
synthesis of glycoproteins including transporters such as the
Na/H antiport.
We have previously shown that two other HMG CoA reduc-
tase inhibitors, namely simvastatin and 25-hydroxycholesterol,
also inhibit cellular Na/H antiport activity with intracellular
acidification [30] and a reduced rate of cell proliferation [30].
From the present study, pravastatin at a concentration of 50
mg/liter had an effect similar to simvastatin at concentrations
ranging from 2.5 to 5 mg/liter [30]. This difference in potency
results from the known affinities of these two drugs for HMG
CoA reductase [31]. A recent study has also demonstrated that
treatment of hyperlipidemic patients with lovastatin in vivo
results in reduced platelet Na/H antiport activity, which is in
agreement with our in vitro studies [32].
Previous work has shown an increased Na/H antiport
activity in leucocytes. The higher prevalence of an atherogenic
lipoprotein profile in these patients [23, 24], the glomerular
mesangial expansion and the abnormalities in Na/H ex-
change and Li/Na countertransport may result from anoma-
lous control of the mevalonate pathway. If changes in cellular
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Fig. 1. The relationship between plasma LDL50 cholesterol levels and leucocyte Na/H
antiport activity in normal subjects (0, A) and
diabetic patients (B: •, patients with
40 - nephropathy;, patients with
normoalbuminuria). Leucocyte Na/H
antiport activity was measured with
intracellular pH clamped to 6.0 by the double
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Fig. 2. Effect of! mmollliter mevalonate on
the inhibition of lymphoblast NaIH antiport
activity by 50 mg/liter pravastatin. Cells were
incubated for 2 days before studies were
carried out (N = 4, P < 0.001 compared
with normal controls or mevalonate treated
cells). Cells treated with both pravastatin and
mevalonate showed no differences in
intracellular pH or Na+/H* antiport activity
from normal cells.
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Na/H antiport activity are related to the abnormal prolifera-
tion of vascular and mesangial cells, then such permissive
changes from raised Na/H antiport activity in diabetic
nephropathy would persist even if LDL cholesterol is raised.
The combination of these lipid and ionic abnormalities may lead
to cardiovascular disease and progressive renal impairment.
Indeed, lipid lowering therapies including simvastatin and pray-
astatin have reduced proteinuria in nondiabetic and diabetic
renal disease [33—35], an effect that is independent of char.ges in
serum lipids [351. Reduced synthesis of other products of the
mevalonate pathway unrelated to cholesterol [27, 291 may
explain some of these findings. Finally, our observations on the
dependence of Na/H antiport activity on a product of HMG
CoA reductase may provide a rationale for a new therapeutic
intervention in diabetic nephropathy that remains to be exam-
ined in clinical trials.
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